News und Analysen

Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around

As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.

Generic drug

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines

Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining